Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Exenatide treatment improves glycemia in adults with type 2 diabetes and has been shown to reduce postprandial hyperglycemia in adolescents with type 1 diabetes. We studied the effects of exenatide on glucose homeostasis in adults with long-standing type 1 diabetes. RESEARCH DESIGN AND METHODS: Fourteen patients with type 1 diabetes participated in a crossover study of 6 months' duration on exenatide (10 μg four times a day) and 6 months off exenatide. We assessed changes in fasting and postprandial blood glucose and changes in insulin sensitivity before and after each study period. RESULTS: High-dose exenatide therapy reduced postprandial blood glucose but was associated with higher fasting glucose concentrations without net changes in hemoglobin A1c. Exenatide increased insulin sensitivity beyond the effects expected as a result of weight reduction. CONCLUSIONS: Exenatide is a promising adjunctive agent to insulin therapy because of its beneficial effects on postprandial blood glucose and insulin sensitivity in patients with type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“While several studies included in their analysis did not find significant changes in HbA1c, they did find a reduction in insulin requirements.15,35,36”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Muniyappa, R., Lee, S., Chen, H., & Quon, M. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00645.2007 · Cited by 1,643 · cited 1×
“Herein, we report the effects of 6 months of therapy with exenatide in patients with long-standing type 1 diabetes focusing on outcomes related to glucose homeostasis, including fasting and postprandial blood glucose and insulin sensitivity, as determined by the reference glucose clamp method (4).”
MethodSelf-citationPostprandial Hyperglycemia and Diabetes Complications
Ceriello, A. (2005) · Diabetes · doi:10.2337/diabetes.54.1.1 · Cited by 945 · cited 1×
“Postprandial glucose has emerged as a strong predictor of cardiovascular risk compared with fasting glucose (6).”
Backgroundα-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Kolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 552
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
Edwards, C. M. B., Stanley, S. A., Davis, R., Brynes, A. E., Frost, G. S., Seal, L. J., Ghatei, M. A., & Bloom, S. R. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.1.e155 · Cited by 464
Gedulin, B. R., Nikoulina, S. E., Smith, P. A., Gedulin, G., Nielsen, L. L., Baron, A. D., Parkes, D. G., & Young, A. A. (2005) · Endocrinology · doi:10.1210/en.2004-1349 · Cited by 242
Schauer, I. E., Snell-Bergeon, J. K., Bergman, B. C., Maahs, D. M., Kretowski, A., Eckel, R. H., & Rewers, M. (2011) · Diabetes · doi:10.2337/db10-0328 · Cited by 230
Rother, K. I., Spain, L. M., Wesley, R. A., Digon, B. J., Baron, A., Chen, K., Nelson, P., Dosch, H.-M., Palmer, J. P., Brooks-Worrell, B., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0773 · Cited by 133
Self-citationExendin-4 Normalized Postcibal Glycemic Excursions in Type 1 Diabetes
Dupré, J., Behme, M. T., & McDonald, T. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032001 · Cited by 127
Features of Hepatic and Skeletal Muscle Insulin Resistance Unique to Type 1 Diabetes
Bergman, B. C., Howard, D., Schauer, I. E., Maahs, D. M., Snell-Bergeon, J. K., Eckel, R. H., Perreault, L., & Rewers, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3172 · Cited by 107
Cited by
Obesity, insulin resistance, and type 1 diabetes mellitus
Polsky, S., & Ellis, S. L. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000170 · Cited by 235
Alfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
“15,35,36 Furthermore, differences in hypo-glycemic events were not substantial or reduced in combination treatment, suggesting that combination treatment does not increase the risk of hypoglycemia.”
BackgroundCombination therapy with GLP ‐1 receptor agonist and SGLT2 inhibitor
DeFronzo, R. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12982 · Cited by 192
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
Dejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A. K., Holst, J. J., Tarnow, L., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00436-2 · Cited by 179
Jones, A. G., McDonald, T. J., Shields, B. M., Hill, A. V., Hyde, C. J., Knight, B. A., & Hattersley, A. T. (2016) · Diabetes Care · doi:10.2337/dc15-0258 · Cited by 178
Exenatide: pharmacokinetics, clinical use, and future directions
Knop, F. K., Brønden, A., & Vilsbøll, T. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1282463 · Cited by 105
Frandsen, C. S., Dejgaard, T. F., Holst, J. J., Andersen, H. U., Thorsteinsson, B., & Madsbad, S. (2015) · Diabetes Care · doi:10.2337/dc15-1037 · Cited by 103
Andreozzi, F., Raciti, G. A., Nigro, C., Mannino, G. C., Procopio, T., Davalli, A. M., Beguinot, F., Sesti, G., Miele, C., & Folli, F. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0985-7 · Cited by 102
Kuhadiya, N. D., Dhindsa, S., Ghanim, H., Mehta, A., Makdissi, A., Batra, M., Sandhu, S., Hejna, J., Green, K., Bellini, N., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1136 · Cited by 101
Bariatric surgery in obese patients with type 1 diabetes
Kirwan, J. P., Aminian, A., Kashyap, S. R., Burguera, B., Brethauer, S. A., & Schauer, P. R. (2016) · Diabetes Care · doi:10.2337/dc15-2732 · Cited by 80
Johansen, N. J., Dejgaard, T. F., Lund, A., Schlüntz, C., Frandsen, C. S., Forman, J. L., Wewer Albrechtsen, N. J., Holst, J. J., Pedersen-Bjergaard, U., Madsbad, S., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30030-9 · Cited by 70
Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes
Kuhadiya, N. D., Ghanim, H., Mehta, A., Garg, M., Khan, S., Hejna, J., Torre, B., Makdissi, A., Chaudhuri, A., Batra, M., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1451 · Cited by 71
Wang, W., Liu, H., Xiao, S., Liu, S., Li, X., & Yu, P. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0282-3 · Cited by 70
“Most studies [15, 17, 27, 31], except for two [12, 16], concluded that this type of therapy could not effectively reduce the dosage of basal insulin.”
BackgroundMethodPark, J., Ntelis, S., Yunasan, E., Downton, K. D., Yip, T. C.-F., Munir, K. M., & Haq, N. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad471 · Cited by 69
Sherr, J., Tsalikian, E., Fox, L., Buckingham, B., Weinzimer, S., Tamborlane, W. V., White, N. H., Arbelaez, A. M., Kollman, C., Ruedy, K. J., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2612 · Cited by 59
GLP-1 Agonists in Type 1 Diabetes Mellitus
Janzen, K. M., Steuber, T. D., & Nisly, S. A. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016651279 · Cited by 53
Gourgari, E., Dabelea, D., & Rother, K. I. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0968-y · Cited by 59
Self-citationKaramanakos, G., Kokkinos, A. D., Dalamaga, Μ., & Liatis, S. (2022) · Current Obesity Reports · doi:10.1007/s13679-022-00477-x · Cited by 49
Pieber, T. R., Deller, S., Korsatko, S., Jensen, L., Christiansen, E., Madsen, J., & Heller, S. R. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12473 · Cited by 43
Herold, K. C., Reynolds, J., Dziura, J., Baidal, D., Gaglia, J., Gitelman, S. E., Gottlieb, P. A., Marks, J., Philipson, L. H., Pop‐Busui, R., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14121 · Cited by 41
Latent autoimmune diabetes in adults (LADA) in Asian and European populations
Kumar, A., & de Leiva, A. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2890 · Cited by 46
Artunc-Ulkumen, B., Pala, H. G., Pala, E. E., Yavasoglu, A., Yigitturk, G., & Erbas, O. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2014.975686 · Cited by 45
“These effects result in increased insülin sensitivity [17].”
BackgroundAdjunctive therapy for glucose control in patients with type 1 diabetes
Harris, K., Boland, C. L., Meade, L. T., & Battise, D. M. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s141700 · Cited by 37
Tandon, S., Ayis, S. A., Hopkins, D. L., Harding, S., & Stadler, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14221 · Cited by 32
Jiang, L., Wang, S.-Q., Ding, B., Zhu, J., Jing, T., Ye, L., Lee, K., Wu, J., & Ma, J. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0765-0 · Cited by 29
Delrue, C., & Speeckaert, M. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179351 · Cited by 28
Bagger, J. I., Grøndahl, M. F. G., Lund, A., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2021) · Diabetes · doi:10.2337/db20-0998 · Cited by 27
Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?
Warnes, H., Helliwell, R., Pearson, S. M., & Ajjan, R. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0496-z · Cited by 27
Kim, Y. J., Hwang, S. D., & Lim, S. K. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00553 · Cited by 24
The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus
Munir, K. M., & Davis, S. N. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1084502 · Cited by 24
Camastra, S., Astiarraga, B., Tura, A., Frascerra, S., Ciociaro, D., Mari, A., Gastaldelli, A., & Ferrannini, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12836 · Cited by 23
Harris, K. B., & Boland, C. L. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1804 · Cited by 23
Karamanakos, G., Barmpagianni, A., Kapelios, C. J., Kountouri, A., Bonou, M. S., Makrilakis, K., Lambadiari, V., Barbetseas, J. D., & Liatis, S. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.10.003 · Cited by 21
Heterologous Expression and Delivery of Biologically Active Exendin-4 by Lactobacillus paracasei L14
Zeng, Z., Yu, R., Zuo, F., Zhang, B., Peng, D., Ma, H., & Chen, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165130 · Cited by 21
GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach
Crisci, I., Aragona, M., Politi, K. S., Daniele, G., & Prato, S. D. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0800-6 · Cited by 19
Kuhadiya, N. D., Prohaska, B. D., Ghanim, H., & Dandona, P. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13609 · Cited by 19
Non-insulin pharmacological therapies for treating type 1 diabetes
Frandsen, C. S., Dejgaard, T. F., Madsbad, S., & Holst, J. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1483339 · Cited by 18
Dejgaard, T. F., Knop, F. K., Tarnow, L., Frandsen, C. S., Hansen, T. S., Almdal, T., Holst, J. J., Madsbad, S., & Andersen, H. U. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007791 · Cited by 17
Bortell, R., Yang, C., Loehn, M., Jurczyk, A., Przewozniak, N., Leehy, L., Herrera, P. L., Shultz, L. D., Greiner, D. L., & Harlan, D. M. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s87253 · Cited by 17
Self-citationHerrera-Ojeda, J. L., Blanco-Palma, R. S., Chávez-Tapia, N. C., Uribe, M., Montalvo-Jave, E. E., & Nuño‐Lámbarri, N. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02621-5 · Cited by 16
Doggrell, S. A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1519547 · Cited by 16
Pharmacological therapies to address obesity in type 1 diabetes
Casu, A., Bilal, A., & Pratley, R. E. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000555 · Cited by 16
Albèr, A., Brønden, A., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12911 · Cited by 14
Johansen, N. J., Dejgaard, T. F., Lund, A., Schlüntz, C., Larsen, E. L., Poulsen, H. E., Goetze, J. P., Møller, H. J., Vilsbøll, T., Andersen, H. U., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14078 · Cited by 14
Battaglia, M., Nigi, L., & Dotta, F. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0690-6 · Cited by 12
Ogawa, S., Nako, K., Okamura, M., Sakamoto, T., & Ito, S. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12314 · Cited by 12
The effects of GLP-1 agonists on HbA1c and insulin dose among patients with type 1 diabetes
Alhowiti, A., & Mirghani, H. O. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1550938 · Cited by 10
Rebelos, E., Anastasiou, I. A., Tentolouris, N., Karagiannis, T., Τσάπας, Α., Ferrannini, E., & Liakos, A. (2025) · HORMONES · doi:10.1007/s42000-025-00704-9 · Cited by 8
Diabetes Technology and Therapy in the Pediatric Age Group
Maahs, D. M., & Shalitin, S. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.2509 · Cited by 8
Abdel‐Rahman, S. M., Al-Shiab, R., Shah, E., Güldan, M., Ak, A. B., Yilmaz, Z. Y., Fidan, D. G., Özbek, L., & Kanbay, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70506 · Cited by 7
Current Issues in Glp-1 Receptor Agonist Therapy for Type 2 Diabetes
Bloomgarden, Z. T., Blonde, L., Garber, A. J., & Wysham, C. (2012) · Endocrine Practice · doi:10.4158/ep12300.ra · Cited by 7
The changing therapeutic armamentarium for patients with type 1 diabetes
Comee, M., & Peters, A. L. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000239 · Cited by 6
Grandy, S., & Shaunik, A. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000643 · Cited by 6
Liu, X., Song, L., Zhang, Y., Li, H., Cui, C., & Liu, D. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1088670 · Cited by 5
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials
Min, T., & Bain, S. C. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2188191 · Cited by 4
Adjunct Therapies In Type 1 Diabetes
Dandona, P., Kuhadiya, N. D., Ghanim, H., & Chaudhuri, A. (2016) · Endocrine Practice · doi:10.4158/ep151113.co · Cited by 3
Diabetes Technology and Therapy in the Pediatric Age Group
Shalitin, S., & Chase, H. P. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.1512 · Cited by 3
Johansen, N. J., Dejgaard, T. F., Lund, A., Vilsbøll, T., Andersen, H. U., & Knop, F. K. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-021861 · Cited by 3
Type 2 treatments for type 1 diabetes
Bloomgarden, Z. T., & Ning, G. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12430 · Cited by 3
Halimi, S. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30243-1 · Cited by 2
Long term (4 years) improved insulin sensitivity following islet cell transplant in type 1 diabetes
Rydzon, B., Monson, R. S., Oberholzer, J., Varady, K. A., Bellin, M. D., & Danielson, K. K. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2972 · Cited by 2
Chaudhuri, A., Kuhadiya, N. D., Ghanim, H., & Dandona, P. (2014) · Diabetes Care · doi:10.2337/dc14-1052 · Cited by 2
Ito, K., Satoh, S., Kondo, Y., Tamura, H., Hasebe, M., & Terauchi, Y. (2022) · Diabetology International · doi:10.1007/s13340-022-00592-z · Cited by 1
Therapy of Type 1 Diabetes Mellitus
Omura, E., Cohan, P., & Peters, A. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_43-2 · Cited by 1
Montanya, E. (2016) · Springer eBooks · doi:10.1007/978-3-319-08982-9_6 · Cited by 1
Characterization of Latent autoimmune diabetes in adults in a region of India
Kumar, A. (2018) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Sarkar, G., Alattar, M., Brown, R. J., Quon, M. J., Harlan, D. M., & Rother, K. I. (2014) · Diabetes Care · doi:10.2337/dc14-1482
Self-citationChaudhuri, A., Kuhadiya, N. D., Ghanim, H., & Dandona, P. (2014)
Caused visual potentials in early diagnostics in patients with type 1 diabetes mellitus
Shtemberg, L. V., Karpov, S., Khodzhayan, A., & Дзибоевич, К. А. (2019) · Medical news of the North Caucasus · doi:10.14300/mnnc.2019.14122
Molecular Markers of Pancreatic β-cell Death
Farr, R. J. (2017) · The Sydney eScholarship Repository (The University of Sydney)
Therapy of Type 1 Diabetes Mellitus
Omura, E., & Peters, A. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_43-1
Therapy of Type 1 Diabetes Mellitus
Omura, E., Cohan, P., & Peters, A. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_43
Do GLP-1 receptor agonists have a place in the treatment of people with type 1 diabetes?
Dejgaard, T. F., Frandsen, C. S., Holst, J. J., & Madsbad, S. (2024) · Medical Research Archives · doi:10.18103/mra.v12i12.6110
Guía de práctica clínica sobre Diabetes Mellitus Tipo 1
(2026) · GuíaSalud eBooks · doi:10.46995/gpc_659
周, 玮. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641306
GLP-1 Receptor Agonists May Reduce Insulin Requirements in New-Onset Type 1 Diabetes
Gregory, J. M. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.010
Metadata
- Authors
- Sarkar, G., Alattar, M., Brown, R. J., Quon, M. J., Harlan, D. M., & Rother, K. I.
- Affiliations
- National Institutes of Health (US)
- University of Maryland, Baltimore (US)
- UMass Memorial Health Care (US)
- Corresponding author
- Rother, Kristina I.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-02-11
- Volume
- 37
- Issue
- 3
- Pages
- 666-670
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3931382
- OpenAlex
- W2152918233
- Cited by
- 74
- References
- 14
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 6 · 2019: 1 · 2018: 6 · 2017: 11 · 2016: 14 · 2015: 14 · 2014: 6
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK079637)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- exenatide, type 1 diabetes, insulin sensitivity, postprandial blood glucose, fasting blood glucose, glucose homeostasis, GLP-1 receptor agonists, weight loss
- MeSH terms
- Exenatide, Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 1, Drug Administration Schedule, Fasting, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin Resistance, Male, Middle Aged, Peptides, Venoms, Cross-Over Studies, Postprandial Period
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.